4.8 Article

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

Journal

CIRCULATION
Volume 117, Issue 25, Pages 3199-3205

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.108.767202

Keywords

renin; drugs; angiotensin; kidney; hypertension

Ask authors/readers for more resources

Background - Pharmacological interruption of the renin-angiotensin system focuses on optimization of blockade. As a measure of intrarenal renin activity, we have examined renal plasma flow (RPF) responses in a standardized protocol. Compared with responses with angiotensin-converting enzyme inhibition (rise in RPF approximate to 95 mL . min(-1) . 1.73 m(-2)), greater renal vasodilation with angiotensin receptor blockers (approximate to 145 mL . min(-1) . 1.73 m(-2)) suggested more effective blockade. We predicted that blockade with the direct oral renin inhibitor aliskiren would produce renal vascular responses exceeding those induced by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Methods and Results - Twenty healthy normotensive subjects were studied on a low-sodium ( 10 mmol/d) diet, receiving separate escalating doses of aliskiren. Six additional subjects received captopril 25 mg as a low-sodium comparison and also received aliskiren on a high-sodium ( 200 mmol/d) diet. RPF was measured by clearance of para-aminohippurate. Aliskiren induced a remarkable dose-related renal vasodilation in low-sodium balance. The RPF response was maximal at the 600-mg dose ( 197 +/- 27 mL . min(-1) . 1.73 m(-2)) and exceeded responses to captopril ( 92 +/- 20 mL . min(-1) . 1.73 m(-2); P < 0.01). Furthermore, significant residual vasodilation was observed 48 hours after each dose ( P < 0.01). The RPF response on a high-sodium diet was also higher than expected ( 47 +/- 17 mL . min(-1) . 1.73 m(-2)). Plasma renin activity and angiotensin levels were reduced in a dose-related manner. As another functional index of the effect of aliskiren, we found significant natriuresis on both diets. Conclusions - Renal vasodilation in healthy people with the potent renin inhibitor aliskiren exceeded responses seen previously with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. The effects were longer lasting and were associated with significant natriuresis. These results indicate that aliskiren may provide more complete and thus more effective blockade of the renin-angiotensin system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Cardiac & Cardiovascular Systems

Digital Care Transformation Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control

Benjamin M. Scirica, Christopher P. Cannon, Naomi D. L. Fisher, Thomas A. Gaziano, David Zelle, Kira Chaney, Angela Miller, Hunter Nichols, Lina Matta, William J. Gordon, Shawn Murphy, Kavi B. Wagholikar, Jorge Plutzky, Calum A. MacRae

CIRCULATION (2021)

Article Cardiac & Cardiovascular Systems

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

David E. Kandzari, Raymond R. Townsend, George Bakris, Jan Basile, Michael J. Bloch, Debbie L. Cohen, Cara East, Keith C. Ferdinand, Naomi Fisher, Ajay Kirtane, David P. Lee, Gary Puckrein, Florian Rader, Joseph A. Vassalotti, Michael A. Weber, Kerry Willis, Eric Secemsky

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2021)

Article Peripheral Vascular Disease

Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study

Manish Saxena, Roland E. Schmieder, Ajay J. Kirtane, Felix Mahfoud, Joost Daemen, Jan Basile, Philipp Lurz, Philippe Gosse, Kintur Sanghvi, Naomi D. L. Fisher, Lars C. Rump, Atul Pathak, Peter J. Blankestijn, Anthony Mathur, Yale Wang, Michael A. Weber, Andrew S. P. Sharp, Michael J. Bloch, Neil C. Barman, Lisa Claude, Yang Song, Michel Azizi, Melvin D. Lobo

Summary: This post-hoc analysis of the RADIANCE-HTN SOLO study found that predictors of response to renal denervation (RDN) included higher baseline daytime ambulatory diastolic blood pressure and use of antihypertensive medications, with orthostatic hypertension potentially predicting response. Obese females also appeared to have a better response to RDN in an interaction model.

JOURNAL OF HUMAN HYPERTENSION (2022)

Article Peripheral Vascular Disease

Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial

Naomi D. L. Fisher, Ajay J. Kirtane, Joost Daemen, Florian Rader, Melvin D. Lobo, Manish Saxena, Josephine Abraham, Roland E. Schmieder, Andrew S. P. Sharp, Philippe Gosse, Lisa Claude, Yang Song, Michel Azizi

Summary: This study investigated the association between plasma renin and aldosterone concentrations and the blood pressure response to renal denervation. The results showed that renal denervation reduced daytime ambulatory systolic blood pressure, but renin and aldosterone concentrations did not predict the blood pressure response to renal denervation.

JOURNAL OF HYPERTENSION (2022)

Article Cardiac & Cardiovascular Systems

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium

David E. Kandzari, Felix Mahfoud, Michael A. Weber, Raymond Townsend, Gianfranco Parati, Naomi D. L. Fisher, Melvin D. Lobo, Michael Bloch, Michael Bohm, Andrew S. P. Sharp, Roland E. Schmieder, Michel Azizi, Markus P. Schlaich, Vasilios Papademetriou, Ajay J. Kirtane, Joost Daemen, Atul Pathak, Christian Ukena, Philipp Lurz, Guido Grassi, Martin Myers, Aloke Finn, Marie-Claude Morice, Roxana Mehran, Peter Juni, Gregg W. Stone, Mitchell W. Krucoff, Paul K. Whelton, Konstantinos Tsioufis, Donald E. Cutlip, Ernest Spitzer

Summary: The clinical implications of hypertension drive the development of device-based therapies. The HARC document integrates expert consensus and regulatory perspectives to address challenges and unmet needs in treating hypertension.

CIRCULATION (2022)

Editorial Material Cardiac & Cardiovascular Systems

Medication adherence in hypertension: lessons learned from renal denervation trials

Naomi D. L. Fisher, Felix Mahfoud

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

A remote hypertension management program clinical algorithm

Hunter Nichols, Christopher P. Cannon, Benjamin M. Scirica, Naomi D. L. Fisher

Summary: Hypertension is a major risk factor for death globally, with poor and stagnant control rates. We have developed a remote hypertension management program that uses digitally transmitted home blood pressure measurements, algorithmic care pathways, and patient-navigator communications to help patients achieve guideline-directed blood pressure goals.

CLINICAL CARDIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial

Michel Azizi, Felix Mahfoud, Michael A. Weber, Andrew S. P. Sharp, Roland E. Schmieder, Philipp Lurz, Melvin D. Lobo, Naomi D. L. Fisher, Joost Daemen, Michael J. Bloch, Jan Basile, Kintur Sanghvi, Manish Saxena, Philippe Gosse, J. Stephen Jenkins, Terry Levy, Alexandre Persu, Benjamin Kably, Lisa Claude, Helen Reeve-Stoffer, Candace McClure, Ajay J. Kirtane

Summary: This study aims to evaluate the long-term effects and safety of ultrasound RDN for patients with resistant hypertension. The results show that after 2 months of treatment, both the uRDN group and the sham group had similar antihypertensive effects, but the uRDN group required fewer additional medications.

JAMA CARDIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network

Alexander J. Blood, Christopher P. Cannon, William J. Gordon, Charlotte Mailly, Taylor MacLean, Samantha Subramaniam, Michela Tucci, Jennifer Crossen, Hunter Nichols, Kavishwar B. Wagholikar, David Zelle, Marian McPartlin, Lina S. Matta, Michael Oates, Samuel Aronson, Shawn Murphy, Adam Landman, Naomi D. L. Fisher, Thomas A. Gaziano, Jorge Plutzky, Benjamin M. Scirica

Summary: This study implemented and evaluated a remote hypertension and cholesterol management program in a diverse healthcare network. The program resulted in improved blood pressure and cholesterol control among patients, regardless of their race, ethnicity, or primary language.

JAMA CARDIOLOGY (2023)

Review Peripheral Vascular Disease

Innovative Remote Management Solutions for the Control of Hypertension

Simin Gharib Lee, Naomi D. L. Fisher

Summary: We are at a critical moment in the delivery of health care for hypertension, as traditional methods are failing and remote management solutions are emerging. With the use of digital technology, home blood pressure measurements, interdisciplinary care teams, and advanced analytics, remote hypertension care is poised to have a significant impact on global cardiovascular health.

HYPERTENSION (2023)

Article Cardiac & Cardiovascular Systems

Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic

Simin Gharib Lee, Alexander J. Blood, Christopher P. Cannon, William J. Gordon, Hunter Nichols, David Zelle, Benjamin M. Scirica, Naomi D. L. Fisher

Summary: The COVID-19 pandemic disrupted traditional health care and led to a drastic decrease in blood pressure assessment. This study analyzed the impact of the pandemic on a remote hypertension management program and found that it was successful in improving blood pressure control and increasing home blood pressure monitoring despite the disruption.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Meeting Abstract Peripheral Vascular Disease

DEMOGRAPHIC FACTORS AFFECTING NOCTURNAL BLOOD PRESSURE VARIABILITY IN THE GENERAL POPULATION: RESULTS OF A LARGE DIGITAL STUDY USING AN OPTICAL BLOOD PRESSURE MONITOR

David Perruchoud, Meritxell Cortes, Josep Sola, Melvin D. Lobo, Gregoire Wuerzner, Naomi D. L. Fisher

JOURNAL OF HYPERTENSION (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

Home Blood Pressure Response to Ultrasound Renal Denervation-A Patient-Level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-Controlled Trials

Andrew Sharp, Michel Azizi, Felix Mahfoud, Naomi Fisher, Melvin Lobo, Michael Weber, Ajay Kirtane

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Meeting Abstract Peripheral Vascular Disease

Persistent Use Of Aktiia 24/7 Blood Pressure Monitor Is Associated With Lower Blood Pressure In Hypertensive Patients

Josep Sola, David Perruchod, Meritxell Cortes, Jay Pandit, Melvin D. Lobo, Gregoire Wuerzner, Naomi D. Fisher, Jay Shah

HYPERTENSION (2022)

Article Engineering, Biomedical

Guidance for the Interpretation of Continual Cuffless Blood Pressure Data for the Diagnosis and Management of Hypertension

Josep Sola, Meritxell Cortes, David Perruchoud, Bastien De Marco, Melvin D. Lobo, Cyril Pellaton, Gregoire Wuerzner, Naomi D. L. Fisher, Jay Shah

Summary: Hypertension is the leading risk factor for death globally. However, the adoption of cuffless blood pressure monitors in clinical practice has been slow due to differences in technology and reluctance to change established standards. This guidance document provides an overview of cuffless devices, highlights their differences from traditional cuff-based monitors, and presents an interpretation framework using a CE-marked cuffless BP device as an example. The widespread use of cuffless monitors in healthcare will require a collaborative and thoughtful process.

FRONTIERS IN MEDICAL TECHNOLOGY (2022)

No Data Available